The next generation of weight-loss drugs

It’s no exaggeration to say that the past decade has revolutionized how we think about and treat obesity. Drugs like semaglutide (Wegovy) and tirzepatide (Zepbound) have dominated headlines, enabling significant weight loss at speeds once considered unthinkable. The market for innovative weight loss medications is booming, with pharmaceutical companies investing heavily in hopes of developing the next blockbuster drug. However, amid this race for market dominance, many experts are questioning whether the amount of weight loss alone is the best measure of these drugs’ usefulness. How can the next generation of obesity treatments meaningfully improve upon the powerful options already available? Joining The Lancet editors Callam Davidson and Miriam Sabin to discuss this question is Professor Steven Heymsfield from the Pennington Biomedical Research Center. This wide-ranging conversation covers exciting pharmaceutical advances and limitations of these treatments, including the significant disparities in access, and why these breakthroughs may have broader societal implications. Send us your feedback! Read all of our content at Check out all the podcasts from The Lancet Group: Continue this conversation on social!

You can listen to The next generation of weight-loss drugs online on Radio and Podcast. Open the player on this page to stream the available audio.

The next generation of weight-loss drugs is an episode from The Lancet Voice by The Lancet Group.

This episode is 38:11 long.

This episode was published on Jul 31, 2025.

Yes. Use the heart button on the episode page to add it to your favorite episodes list.

Yes. This page shows related episodes from The Lancet Voice when more episodes are available from the podcast feed.